Pzena Investment Management added 1,097,961 shares of Accenture during the fourth quarter, bringing its disclosed stake to approximately $614 million based on ACN's December 31 closing price of $329.47. The addition represents a 140% increase quarter-over-quarter for the New York value manager, which oversees $38 billion in global equity strategies.

The buy comes as Accenture traded down 18% from its July highs, closing the year at a forward P/E of 24.3x versus a five-year median of 27.1x. Revenue growth decelerated to 1.5% year-over-year in the September quarter, the slowest pace since pandemic lockdowns, as discretionary IT budgets tightened across North American enterprise clients. Bookings held at $20.1 billion, flat sequentially, with management guiding to 3-6% organic growth for fiscal 2025. Pzena's cost basis is unclear from the 13F alone, but the timing suggests accumulation during the August-October window when ACN traded between $310 and $335.

The position matters because Pzena runs concentrated portfolios with 30-50 names and holds for 3-5 years when thesis integrity remains. The firm's flagship U.S. Value strategy returned 8.2% annualized over the past decade, lagging the Russell 1000 Value by 110 basis points, but outperforming during the 2022 drawdown by 340 basis points. Accenture now ranks among Pzena's top 15 holdings by dollar weight, alongside energy and financial names that define the book. The conviction signal is the size—1.1 million shares is not a pilot stake. It is a view that consulting margin pressure is transitory and that generative AI implementation cycles will require exactly the kind of systems integration Accenture monetizes at 40% gross margins.

The trade also reflects a calculation about corporate IT spend normalization. CIO surveys from Gartner show 2024 budgets up 3.9%, the slowest growth in four years, but 68% of respondents plan to increase AI-related spending in the next 18 months. Accenture holds 738 generative AI client engagements as of November, up from 300 in May. If those convert to multi-year transformation contracts at historical $12-18 million average deal sizes, the revenue inflection arrives in the second half of fiscal 2025. Pzena is pricing in that outcome before consensus estimates adjust.

Operators should track Accenture's December quarter results, due late March, for sequential bookings acceleration and any guide raise on fiscal 2025 margins. Watch whether North American consulting revenue, which fell 2% year-over-year in September, returns to growth. The stock has since rallied 11% from December lows, closing Friday at $365.22, which implies Pzena's stake now exceeds $680 million on paper. That mark-to-market gain in 90 days is either early-cycle prescience or premium paid for a thesis that takes 24 months to validate.

The filing does not disclose whether Pzena added in October's dip to $310 or November's climb past $340. That $30 spread determines whether this is patient value capture or momentum chase. Either way, the position is large enough to move Pzena's quarterly attribution if Accenture rerates 200 basis points higher on margin expansion. The next 13F, due May 15, will show whether Pzena held through the January rally or took profit into strength.